I can live to an old lady with these kidneys and that is phenomenal
For decades, lupus has been a disease of management rather than resolution — a slow negotiation between the body and its own misdirected defenses. Now, in early trials at University College London Hospitals, a therapy borrowed from cancer medicine has done something once considered beyond reach: it has persuaded the immune system to forget its grievances and begin again. Five of six patients treated with genetically engineered CAR-T cells remain in remission more than eighteen months later, some free of all medication, their damaged organs quietly healing. Whether this reprieve will hold across years and larger populations remains the open question, but the direction of travel has shifted.
- Lupus, which turns the immune system into an attacker of its own joints, skin, and organs, has pushed thousands of patients — ninety percent of them women — toward dialysis, organ failure, and early death.
- The CAR-T approach demands a radical wager: patients undergo chemotherapy and sign documents acknowledging the possibility of dying, all to allow genetically rewired T cells to wage a deliberate civil war inside the body.
- The engineered cells hunt and destroy rogue B cells wholesale, healthy ones included, creating a temporary immunological void from which an entirely reset immune system can regenerate.
- Five of the first six patients treated remain in remission over eighteen months on, with one patient's kidneys, heart, and lungs recovering sufficiently to change her life's entire trajectory.
- Researchers are cautiously optimistic but honest: long-term durability is unproven, and trials for multiple sclerosis and rheumatoid arthritis are only beginning to test how far this reset principle can reach.
Katie Tinkler has lived with lupus since she was twenty — three decades of steroids kept close at hand, of mornings that required medication forty-five minutes before she could lift a cup of tea. She worked, raised children, and managed. Then, in the past decade, the disease stopped being manageable. It began destroying her heart, her lungs, her kidneys. She was edging toward dialysis. Lupus had become a countdown.
In November 2024, she underwent an experimental treatment at University College London Hospitals designed to do something the disease had never allowed: reset her immune system entirely. The therapy works by engineering a patient's own T cells to seek out and destroy the rogue B cells responsible for lupus — cells that, instead of protecting the body, produce antibodies that attack it. Once the malfunctioning B cells are eliminated, healthy ones regenerate, and the immune system effectively starts over.
The process was not without risk. Chemotherapy preceded the infusion. Katie signed documents acknowledging she might not survive. Eighteen months later, she takes no lupus medication. Her kidneys have recovered. Her heart and lungs have healed. She talks about skiing, triathlons, and saying yes to anything.
Katie was among the first six patients treated in this early trial. Five remain in remission more than eighteen months on; one experienced a flare at eleven months but still shows improvement. The results, presented at the European Congress of Rheumatology, mark some of the earliest evidence that CAR-T therapy — already used in blood cancers — can interrupt autoimmune disease at its root.
Lupus affects around fifty thousand people in the UK, the vast majority of them women diagnosed in young adulthood. Dr. Maria Leandro of UCLH was careful to note that long-term durability remains unknown, but called the findings a significant step toward a possible cure. The horizon extends further still: trials for multiple sclerosis are already underway, and researchers see substantial potential in rheumatoid arthritis. The practical questions — how long remission lasts, how broadly the treatment will work, how accessible it will become — remain unanswered. For Katie, the answer that matters is simpler: she can live to be an old woman with the kidneys she has now, and that, she says, is phenomenal.
Katie Tinkler sits in her Surrey kitchen, a glitterball catching the light above her head, and describes a life she thought she'd lost. Thirty years ago, when she was twenty, lupus entered her body and never left—a disease where the immune system turns traitor, attacking joints, skin, and vital organs as if they were foreign invaders. For three decades, she managed. She worked as a fitness instructor. She raised children. But she always kept steroids in her pocket, because mornings meant pain so severe she couldn't lift a cup of tea without medication taken forty-five minutes before she could even get out of bed.
In the past decade, the disease accelerated into something darker. Lupus began destroying her heart, her lungs, her kidneys. Hospital stays stretched longer. She edged toward needing dialysis. The condition that had been a constant companion became a countdown. "Lupus at its worst was in bed, unable to move, going downhill rapidly, possibly dying," she said. Then, in November 2024, she underwent an experimental treatment at University College London Hospitals that would fundamentally rewire her immune system.
The therapy works on a deceptively simple principle: engineer a civil war inside the body. Lupus happens because B cells—white blood cells that normally protect against infection—go rogue and produce antibodies that attack the body instead. Scientists took millions of Katie's own T cells, the other major type of immune defender, and genetically modified them in the laboratory. They rewired the T cells' targeting mechanism so that instead of fighting infection, these engineered cells would hunt down and destroy B cells. The modified cells were then returned to her body, where they systematically eliminated both the malfunctioning B cells and the healthy ones. Months later, new healthy B cells regenerated, effectively resetting the entire immune system.
It was not a gentle process. The treatment involved chemotherapy to prevent her own body from rejecting the modified cells. Katie signed documents acknowledging she might die. There were no guarantees. But eighteen months later, she is still well. She no longer takes any lupus medication. Her kidneys have recovered enough that she will not need dialysis. Her heart and lungs have healed. "I can live to an old lady with these kidneys and that is phenomenal," she said. The energy in her voice when describing her life now—skiing, saying yes to anything, living like a normal person—carries the weight of someone who has returned from the edge.
Katie was one of the first six patients treated with this approach, known as CAR-T or chimeric antigen receptor T-cell therapy. Five of the six remain in remission more than eighteen months after treatment. One patient experienced a lupus flare after eleven months but still shows improvement. The results, presented at the European Congress of Rheumatology, represent some of the earliest evidence that CAR-T therapy—already approved for certain blood cancers—can reset autoimmune disease.
Lupus affects around fifty thousand people in the UK, and ninety percent of them are women, typically diagnosed in young adulthood. The disease causes joint pain, skin conditions, and organ damage that can be life-altering. For those living with it, remission without medication is not just medical progress; it is the difference between a life constrained by disease and a life actually lived. Dr. Maria Leandro, a consultant rheumatologist at UCLH, cautioned that the long-term durability remains unknown. "If we were to have patients in remission for three-to-five years consistently, that would be a major gain in lupus," she said. "This is clearly a significant step forward towards a possible cure."
The potential extends beyond lupus. Multiple sclerosis and rheumatoid arthritis work through similar mechanisms—the immune system attacking the body's own cells. Clinical trials for MS are already underway. Dr. Claire Roddie from UCL noted the scale of opportunity: "Rheumatoid arthritis, for instance, huge number of patients affected by this disorder... huge potential." For now, the questions are practical ones: How long will remission last? Will the treatment work as well in larger, more diverse patient populations? Will it be accessible beyond early trials? Katie does not know the answers. She only knows that she wants to climb mountains, attempt a triathlon again, and say yes to as many things as possible. For someone who once struggled to lift a cup of tea, that is everything.
Notable Quotes
I've never been this good. I'm living like a normal person, I'm literally saying yes to anything.— Katie Tinkler, lupus patient treated with CAR-T therapy
If we were to have patients in remission for three-to-five years consistently, that would be a major gain in lupus. This is clearly a significant step forward towards a possible cure.— Dr. Maria Leandro, consultant rheumatologist at UCLH
The Hearth Conversation Another angle on the story
Why does this treatment work when so many others have failed to put lupus into remission?
Because it doesn't try to suppress the immune system—it resets it entirely. Instead of damping down the attack, you engineer the immune system to destroy the cells causing the problem, then let healthy ones grow back. It's not management; it's reconstruction.
But that sounds incredibly risky. You're essentially weaponizing the patient's own cells.
It is risky. Katie had to sign documents acknowledging she might die. The chemotherapy alone is brutal. But lupus at its worst is also a death sentence—organ failure, kidney damage, a slow decline. For someone like Katie, the risk became worth taking.
Five out of six patients in remission is remarkable, but that's a tiny sample. What happens when you scale this up?
That's the honest question nobody can answer yet. These are the first patients. We don't know if it works as well in people with different genetics, different disease severity, different bodies. We don't even know how long the remission lasts—could be three years, could be ten, could be permanent.
If it does work broadly, what changes?
Everything. Ninety percent of lupus patients are women. Many spend their lives managing flare-ups, taking steroids, watching their organs deteriorate. If you could offer them remission without medication, you're not just treating a disease—you're giving them their lives back.
You mentioned MS and rheumatoid arthritis. Why those?
Because they're autoimmune diseases with the same basic problem—B cells gone rogue, attacking the body. If you can reset the immune system in lupus, the same principle should work for conditions affecting millions more people. That's why the researchers are already running trials.
What's the catch?
Access, cost, and time. This isn't a pill. It requires genetic engineering, chemotherapy, hospitalization, months of recovery. It will be expensive. And we won't know for years whether remission holds. But for Katie, who was heading toward dialysis and organ failure, it was worth everything.